Floatz logo

Vgn-R08B

Type II Gaucher Disease

Xinhua Hospital, Shanghai Jiao Tong University School of Medicinegene_therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Type II Gaucher Disease cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Prevail Therapeutics
Phase 1/2CCC
ly3884961
Prevail Therapeutics
Phase 1/2CCC
Rapamycin
Prevail Therapeutics
Phase 1/2CCC
IDURONIDASE, .ALPHA.-L-(8-HISTIDINE) (HUMAN)
University of California, San Francisco
Phase 1CC

Same molecule, other indications

Vgn-R08B is also rated in:

Gaucher Disease Type 3Dormant
CCC
Indicative ·
48 / 100
View asset →
Parkinson diseaseDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →